Desitin Arzneimittel GmbH   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Hamburg Germany (1919)
Status: No NME R&D (1919)

Organization Overview

First Clinical Trial
2006
NCT00391534
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Desitin Arzneimittel GmbH

Active Ingredients

Drugs in Phase 3 Trials (4)

oxcarbazepine (trileptal) (1 trial)

Piribedil (1 trial)

pramipexole (mirapex) (1 trial)

ropinirole (Requip) (1 trial)

Drugs in Phase 2 Trials (1)

Sulthiame (Trolone) (1 trial)

Drugs in Phase 1 Trials (2)

carbidopa (sinemet) (1 trial)

levodopa (larodopa) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Epilepsies, Partial (Phase 3)

Epilepsy (Phase 3)

Parkinson Disease (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 7